Clinical Trial

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Study acronym: STELLAR-311
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Protocol Amendment History 4 changes
notable Trial sites expanded: 117 -> 120 locations 2026-08-08
notable Trial sites expanded: 97 -> 117 locations 2026-07-23
notable Trial sites expanded: 80 -> 97 locations 2026-07-10
notable Trial sites expanded: 66 -> 80 locations 2026-04-18
Trial Details
NCT Number NCT06943755
Lead Sponsor Exelixis
Conditions Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
Enrollment 440 participants
Start Date 2025-07-21
Primary Completion 2029-06-30 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-07